Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Myriad Genetics, |
RCV002289677 | SCV004932965 | likely pathogenic | Li-Fraumeni syndrome 1 | 2024-02-13 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 29979965]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 19556618, 19127094]. |
| Genome- |
RCV002289677 | SCV002583168 | pathogenic | Li-Fraumeni syndrome 1 | 2022-06-18 | criteria provided, single submitter | clinical testing | |
| Genome- |
RCV000492742 | SCV002582606 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-06-18 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000821569 | SCV000962331 | pathogenic | Li-Fraumeni syndrome | 2022-10-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects TP53 function (PMID: 12826609, 29979965, 30224644). Advanced modeling of experimental studies (such as gene expression, population dynamics, functional pathways, and cell-cycle effects in cell culture) performed at Invitae indicates that this missense variant is expected to disrupt TP53 protein function. ClinVar contains an entry for this variant (Variation ID: 428902). This missense change has been observed in individuals with Li-Fraumeni syndrome (PMID: 19127094, 19556618; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces asparagine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 131 of the TP53 protein (p.Asn131Ile). |
| Ambry Genetics | RCV000492742 | SCV000581162 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-09-02 | criteria provided, single submitter | clinical testing | The p.N131I variant (also known as c.392A>T), located in coding exon 4 of the TP53 gene, results from an A to T substitution at nucleotide position 392. The asparagine at codon 131 is replaced by isoleucine, an amino acid with dissimilar properties. In one family, this alteration was detected in a woman diagnosed with early-onset bilateral breast cancer, metachronous colon cancers, lung cancer and numerous basal cell carcinomas, and whose grandson was diagnosed with a choroid plexus carcinoma (Agarwalla P et al Pediatr Neurosurg. 2008;44(6):501-8; Gonzalez KD et al. J. Med. Genet., 2009 Oct;46:689-93; O'Neill AF et al. Pediatr Blood Cancer, 2018 Feb;65). This variant is in the DNA binding domain of the TP53 protein and is reported to have loss of transactivation in yeast based assays (IARC TP53 database: Kato S et al. Proc. Natl. Acad. Sci. USA 2003 Jul;100:8424-9). Studies conducted in human cell lines indicate this alteration is deficient at growth suppression (Kotler E et al. Mol. Cell 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). Another alteration at the same codon, p.N131Y (c.391A>T), also has deficient function and has been detected de novo in a patient meeting Chompret criteria. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Dr. |
RCV005899767 | SCV006900439 | not provided | Squamous cell lung carcinoma | no classification provided | in vitro |